Infliximab antibody | AbD19370_hIgG1

100% Secure


Human anti Infliximab

Anti-infliximab antibody is a non-neutralizing anti-idiotypic antibody in IgG1 format, suitable for bioanalytical assays for infliximab or biosimilars. It does not inhibit the binding of infliximab to TNF alpha; it is ideal for PK bridging ELISA to measure total drug and as calibrator in ADA assay.

Product Type
Monoclonal Antibody
Clone
AbD19370_hIgG1
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
HCA215 E 0.1 mg
Human anti Infliximab, clone AbD19370_hIgG1, is an anti-idiotypic antibody that specifically recognizes free infliximab monoclonal antibody and infliximab when bound to its target, Tumor Necrosis Factor Alpha (TNFα). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

Human anti Infliximab, clone AbD19370_hIgG1 is not paratope-specific and is non-inhibitory; it binds to an epitope outside the infliximab binding site. This epitope is shared with other chimeric antibodies that are highly homologous to infliximab including the chimeric antibody cetuximab, but not rituximab. The antibody can be used as a detection antibody in a pharmacokinetic (PK) assay in the bridging format to measure total drug (free, partially bound and fully bound). As it is a fully human antibody, it can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.

Infliximab (branded as Remicade®) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. It is directed against TNFα and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNFα expressing T-lymphocytes.

View a summary of all anti-infliximab antibodies.

Product Details

Product Form
Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line.
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline.
Preservative Stabilisers
0.01% Thiomersal
Immunogen
Infliximab
Affinity
The monovalent intrinsic affinity of this antibody was measured as KD=1.4 nM by real time, label-free molecular interaction analysis on immobilized infliximab.
Approx. Protein Concentrations
Antibody concentration 0.5 mg/ml.

Storage Information

Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
12 months from date of despatch.

More Information

Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Inflectra® is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS™ is a trademark of Merck Sharp & Dohme Corp.
Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory
For research purposes only

Applications of Infliximab antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
ELISA
This product may be used in a direct ELISA, as a bridging antibody in ADA assays or as a detection antibody in an Infliximab bridging ELISA when conjugated to HRP together with HCA212 as the capture reagent.
Protocol: PK bridging ELISA to measure total drug
Protocol: ADA bridging ELISA

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Infliximab HCA212 0.1 mg E
LYNX Rapid HRP Antibody Conjugation Kit LNK002P 3 Conjugations For 400µg Antibody CJ
Mouse anti Human IgG (Fc) CH2 Domain:HRP MCA647P 0.2 mg C* E
Recombinant Human TNF Alpha PHP051 50 µg E FN WB